Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.
Sims JD, Taguiam JM, Alonso-Valenteen F, Markman J, Agadjanian H, Chu D, Lubow J, Abrol R, Srinivas D, Jain A, Han B, Qu Y, Mirzadehgan P, Hwang JY, Rentsendorj A, Chung A, Lester J, Karlan BY, Gray HB, Gross Z, Giuliano A, Cui X, Medina-Kauwe LK.
Sims JD, et al.
J Control Release. 2018 Feb 10;271:127-138. doi: 10.1016/j.jconrel.2017.12.024. Epub 2017 Dec 27.
J Control Release. 2018.
PMID: 29288681
Free PMC article.